Salvage therapy for ovarian cancer.

被引：13

作者：

Garcia A.A. ^{[1
]}

机构：

[1] Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, MS 34, Los Angeles, 90089-9177, CA

来源：

Current Oncology Reports | 1999年 / 1卷 / 1期

关键词：

Ovarian Cancer; Paclitaxel; Docetaxel; Clin Oncol; Epithelial Ovarian Cancer;

D O I：

10.1007/s11912-999-0012-8

中图分类号：

学科分类号：

摘要：

The majority of patients with ovarian cancer will relapse after initial chemotherapy and will be candidates for salvage treatment. Currently, five agents show clear activity in patients with platinum- and paclitaxel-resistant disease: topotecan, oral etoposide, liposomal doxorubicin, gemcitabine, and, possibly, docetaxel. In addition, other agents have activity in platinum-resistant patients: vinorelbine, tamoxifen, ifosfamide, altretamine, 5-fluorouracil with leucovorin, and, possibly, irinotecan. Furthermore, selected patients may benefit from other therapeutic approaches such as surgery or radiation therapy.

引用

页码：64 / 70

页数：6

共 196 条

[31]

Blessing JA(1995)Gemcitabine (gem) in cisplatin-resistant ovarian cancer [abstract] Proc ASCO 14 272-272

[32]

Ball H(1995)Docetaxel J Clin Oncol 13 2643-2655

[33]

Trimble EL(1995)Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681

[34]

Adams JD(1996)Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum Clin Cancer Res 2 837-842

[35]

Vena D(1994)Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer J Clin Oncol 12 2301-2308

[36]

Einzig AI(1997)Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated review Eur J Cancer 33 2167-2170

[37]

Wiernik PH(1998)A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 3362-3368

[38]

Sasloff D(1999)Docetaxel for patients with ovarian cancer refractory to paclitaxel, an update [abstract] Proc Asco 18 368a-368a

[39]

Fennelly C(1997)Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 987-993

[40]

Aghajanian F(1999)Interim analysis of a non-comparative, multicenter study of DOXIL/CAELYX in the treatment of patients with refractory ovarian cancer [abstract] Proc ASCO 18 360a-360a

← 1 2 3 4 5 6 7 8 9 10 →